Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.22B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.39M
Average 1.48M
MLYS Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Mineralys Therapeutics, Inc.NASDAQ: MLYS
Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other current liabilities remains negative
Q2 FY2026 other current liabilities was $0, compared with $2.62M a year earlier. Over 3 fiscal years it compounded at +124.8% a year.
Context
- Other current liabilities amounted to 0.0% of total assets at the end of Q2 FY2026, down 0.8 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.56M USD
- Year-over-year change
- +110.9%
- 4-year CAGR
- +121.7%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.56M | +110.9% |
| FY2024 | 2024-12-31 | 3.58M | +124.0% |
| FY2023 | 2023-12-31 | 1.6M | +140.5% |
| FY2022 | 2022-12-31 | 665K | +112.5% |
| FY2021 | 2021-12-31 | 313K | — |
Other Current Liabilities vs competitors
How MLYS compares with its peers on the latest reported figures
- MLYS's Jun 2026 other current liabilities of $0 is the 6th highest of the 7 companies compared; the peer median is $5.43M.
- Its year-over-year change of -100.0% is the 6th highest of 7, against a peer median of +111.1%.
- Other current liabilities amounts to 0.0% of total assets for MLYS, versus a peer median of 3.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $204.6M | +521.1% | -2.3% | 24.1% | |
| Mar 2026 | $21.7M | +104.9% | — | 33.7% | |
| Mar 2026 | $5.44M | +448.2% | +29.4% | 5.4% | |
| Mar 2026 | $5.42M | -25.5% | +13.2% | 1.3% | |
| Mar 2026 | $741K | +117.3% | +27.4% | 1.4% | |
| Jun 2026 | $0 | -100.0% | +124.8% | 0.0% | |
| Jun 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding MLYS) | $5.43M | +111.1% | +20.3% | 3.4% | |
Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10.61M | 87.7M | 49.3M | 114.09M | 172.92M |
| Short-term Investments | 0 | 22.41M | 187.26M | 84.1M | 483.71M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 50K | 2.7M | 12.54M | 7.16M | 4.75M |
| Total Current Assets | 11.12M | 112.81M | 249.1M | 205.35M | 661.39M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 53K | 38K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 2.48M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3K | 1.63M | 51K | 499K | 382K |
| Total Non-current Assets | 3K | 1.63M | 2.53M | 552K | 420K |
| Total Assets | 11.13M | 114.44M | 251.64M | 205.9M | 661.81M |
| Account Payables | 763K | 1.91M | 601K | 479K | 2.02M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 313K | 665K | 1.6M | 3.58M | 7.56M |
| Total Current Liabilities | 5.05M | 8.07M | 10.48M | 14.65M | 15.11M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 29M | 158.64M | 0 | 0 | 0 |
| Total Non-current Liabilities | 29M | 158.64M | 0 | 0 | 0 |
| Total Liabilities | 34.05M | 166.71M | 10.48M | 14.65M | 15.11M |
| Common Stock | 1K | 1K | 4K | 5K | 8K |
| Retained Earnings | (23.01M) | (52.81M) | (124.71M) | (302.52M) | (457.17M) |
| Accumulated OCI | 0 | 0 | (251.64M) | 0 | 0 |
| Other Stockholders Equity | (29M) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (22.93M) | (52.27M) | 241.15M | 191.26M | 646.69M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | (10.61M) | (87.7M) | (49.3M) | (114.09M) | (172.92M) |
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$13.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.